

## **Travel Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-07-21 | 150 pages | Global Market Insights

### **AVAILABLE LICENSES:**

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

### **Report description:**

The Global Travel Vaccines Market was valued at USD 4.9 billion in 2024 and is estimated to grow at a CAGR of 9.9% to reach USD 12.1 billion by 2034. This market is gaining momentum due to a mix of global health awareness, rapid advancements in vaccine development, and evolving international travel patterns. Increasing recognition of regional disease risks and the role of vaccination in preventing illness while abroad is fueling widespread demand. Government health policies, education efforts, and digital health platforms are reinforcing the critical role vaccines play in pre-travel planning.

As global travel recovers and diversifies, preventive immunization becomes a crucial component in maintaining public health, particularly in areas with limited healthcare infrastructure. Technology is enhancing vaccine production and delivery through innovations that streamline logistics, reduce costs, and improve shelf life. These shifts are enabling wider adoption of travel vaccines globally, especially in underserved and high-risk areas. Travel vaccines are administered to protect travelers from infections like rabies, typhoid, yellow fever, and hepatitis. The market is segmented into mono and combination vaccines, distributed through both public and private healthcare channels.

The mono vaccines segment generated USD 2.9 billion in 2024 and is forecast to reach USD 7.1 billion by 2034 at a CAGR of 9.7%. Their continued dominance stems from targeted protection and lower risk of side effects, making them a preferred choice for travelers heading to areas with poor sanitation and high disease prevalence. Immunizations for diseases like typhoid and rabies are often recommended depending on the destination, duration of travel, and local healthcare conditions.

In terms of vaccine type, the Hepatitis A segment held a 20.2% share in 2024. Its strong position is linked to its essential role in protecting against food and water-borne illness, particularly in regions across Latin America, Asia, and Africa where sanitation remains a major concern. Even short visits can pose a risk, especially for those consuming local cuisine or staying in non-commercial accommodations. Due to the high transmission risk, global health authorities strongly recommend Hepatitis A vaccination as a standard measure for most international travelers.

United States Travel Vaccines Market generated USD 1.9 billion in 2024 and is expected to grow at a CAGR of 9.3% between 2025 and 2034. This growth aligns with increasing international departures and proactive public health initiatives. Federal agencies are supporting market expansion by encouraging travel-related immunization through updated guidelines and outreach efforts. The

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

increase in outbound tourism, combined with rising disease awareness, continues to drive vaccine uptake across the country. Leading players in the Global Travel Vaccines Market include Meiji Group, Dynavax Technologies, Serum Institute of India, Sanofi, GlaxoSmithKline plc (GSK), Valneva SE, Bharat Biotech, Pfizer, CSL, Emergent BioSolutions, Merck, and Bavarian Nordic. To maintain a competitive advantage, companies in the travel vaccines sector are implementing strategies centered around innovation, expansion, and accessibility. Investments in advanced technologies like mRNA and single-dose solutions are helping improve vaccine efficacy and delivery. Firms are enhancing their manufacturing scalability to meet global demand, particularly in regions with limited access. Strategic partnerships with public health institutions and travel health providers are being leveraged to increase awareness and distribution reach.

□

## Comprehensive Market Analysis and Forecast

- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter's Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis

### Table of Contents:

#### Report Content

#### Chapter 1 Methodology and Scope

- 1.1 Market scope and definition
- 1.2 Research design
  - 1.2.1 Research approach
  - 1.2.2 Data collection methods
- 1.3 Data mining sources
  - 1.3.1 Global
  - 1.3.2 Regional/Country
- 1.4 Base estimates and calculations
  - 1.4.1 Base year calculation
  - 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
  - 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations

#### Chapter 2 Executive Summary

- 2.1 Industry 360 synopsis
- 2.2 Key market trends
  - 2.2.1 Regional trends
  - 2.2.2 Vaccine type trends
  - 2.2.3 Disease type trends
  - 2.2.4 Application trends
  - 2.2.5 Age group trends
  - 2.2.6 End use trends
- 2.3 CXO perspectives: Strategic imperatives
  - 2.3.1 Key decision points for industry executives
  - 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Chapter 3 Industry Insights

### 3.1 Industry ecosystem analysis

### 3.2 Industry impact forces

#### 3.2.1 Growth drivers

##### 3.2.1.1 Rising outbound or international travel

##### 3.2.1.2 Growing awareness of preventive measures

##### 3.2.1.3 Advancements in vaccine formulation and production efficiency

#### 3.2.2 Industry pitfalls and challenges

##### 3.2.2.1 Logistical & infrastructure challenges

##### 3.2.2.2 Stringent regulatory approval process

#### 3.2.3 Market opportunities

##### 3.2.3.1 Customized & combination vaccines

##### 3.2.3.2 Growing travel and tourism

### 3.3 Growth potential analysis

### 3.4 Pipeline analysis

### 3.5 Technology landscape

#### 3.5.1 Current technological trends

#### 3.5.2 Emerging technologies

### 3.6 Regulatory landscape

### 3.7 Gap analysis

### 3.8 Future market trends

### 3.9 Porter's analysis

### 3.10 PESTEL analysis

## Chapter 4 Competitive Landscape, 2024

### 4.1 Introduction

### 4.2 Company matrix analysis

### 4.3 Company market share analysis

#### 4.3.1 North America

#### 4.3.2 Europe

#### 4.3.3 Asia Pacific

### 4.4 Competitive analysis of major market players

### 4.5 Competitive positioning matrix

### 4.6 Key developments

## Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021-2034 (\$ Mn)

### 5.1 Key trends

### 5.2 Mono vaccines

### 5.3 Combination vaccines

## Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 (\$ Mn)

### 6.1 Key trends

### 6.2 Hepatitis A

### 6.3 Meningococcal diseases

### 6.4 Influenza

### 6.5 Diphtheria, pertussis, tetanus (DPT)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.6 Rabies
- 6.7 Yellow fever
- 6.8 Typhoid
- 6.9 Measles, mumps, and rubella (MMR)
- 6.10 Hepatitis B
- 6.11 Other disease types

#### Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 (\$ Mn)

- 7.1 Key trends
- 7.2 Outbound travel
- 7.3 Domestic travel

#### Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 (\$ Mn)

- 8.1 Key trends
- 8.2 Pediatric
- 8.3 Adult

#### Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 (\$ Mn)

- 9.1 Key trends
- 9.2 Hospitals
  - 9.2.1 Public
  - 9.2.2 Private
- 9.3 Specialty clinics
- 9.4 Other end use

#### Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)

- 10.1 Key trends
- 10.2 North America
  - 10.2.1 U.S.
  - 10.2.2 Canada
- 10.3 Europe
  - 10.3.1 Germany
  - 10.3.2 UK
  - 10.3.3 France
  - 10.3.4 Spain
  - 10.3.5 Italy
  - 10.3.6 Netherlands
- 10.4 Asia Pacific
  - 10.4.1 Japan
  - 10.4.2 China
  - 10.4.3 India
  - 10.4.4 Australia
  - 10.4.5 South Korea
- 10.5 Latin America
  - 10.5.1 Brazil
  - 10.5.2 Mexico
  - 10.5.3 Argentina

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.6 Middle East and Africa

10.6.1 South Africa

10.6.2 Saudi Arabia

10.6.3 UAE

Chapter 11 Company Profiles

11.1 Bavarian Nordic

11.2 Bharat Biotech

11.3 CSL

11.4 Dynavax Technologies

11.5 Emergent BioSolutions

11.6 GlaxoSmithKline plc (GSK)

11.7 Meiji Group

11.8 Merck

11.9 Pfizer

11.10 Sanofi

11.11 Serum Institute of India

11.12 Valneva SE

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Travel Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-07-21 | 150 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

